Causeway Therapeutics develops microRNA-based therapeutics targeting musculoskeletal diseases such as osteoarthritis and tendinopathy, aiming to improve health outcomes in age-related and fibrotic disorders. Their clinical-stage pipeline focuses on redefining the treatment landscape for these conditions, enhancing the quality of life for aging populations.
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Musculoskeletal diseases like osteoarthritis and tendinopathy significantly impair the quality of life, especially in aging populations. Current treatments often fail to address the underlying molecular mechanisms driving these conditions, leading to limited efficacy and the need for more innovative therapeutic approaches.
Solution
Causeway Therapeutics is developing microRNA (miRNA)-based therapeutics designed to target the molecular pathways implicated in musculoskeletal diseases. Their approach aims to modulate gene expression at the post-transcriptional level, offering a more targeted and potentially disease-modifying treatment option. By focusing on age-related and fibrotic disorders affecting the musculoskeletal system, Causeway Therapeutics seeks to improve patient outcomes and redefine the treatment landscape for conditions like osteoarthritis and tendinopathy. Their clinical-stage pipeline is focused on advancing miRNA therapeutics through clinical trials to demonstrate safety and efficacy.
Target Audience
The primary target audience includes patients suffering from musculoskeletal diseases such as osteoarthritis and tendinopathy, as well as healthcare providers specializing in rheumatology, orthopedics, and geriatric medicine.
Features
- Utilizes microRNA (miRNA) to modulate gene expression related to musculoskeletal diseases.
- Focuses on age-related indications with potential to redefine healthy aging.
- Clinical-stage Tendinopathy program in active development.
- Pre-clinical programs targeting osteoarthritis and other age-related conditions.
- CardioMiR program targeting heart disease.
- DermaMiR™ program targeting skin-aging.
- TenoMiR program targeting Tendinopathy.